← All trials
NCT03691610
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2018
- Primary completion
- Jun 30, 2020
- Completion date
- Jun 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 940
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- hepatitis b vaccine (recombinant)
- rotavirus vaccine, live, oral, pentavalent
- rotavirus vaccine, live, oral, pentavalent
- live attenuated varicella vaccine
- live attenuated varicella vaccine
- measles, mumps, and rubella vaccine
- measles, mumps, and rubella vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.